Mathes Company’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-5,765
| Closed | -$791K | – | 131 |
|
|
2024
Q1 | $791K | Hold |
5,765
| – | – | 0.3% | 71 |
|
|
2023
Q4 | $783K | Hold |
5,765
| – | – | 0.32% | 66 |
|
|
2023
Q3 | $705K | Hold |
5,765
| – | – | 0.33% | 68 |
|
|
2023
Q2 | $732K | Buy |
+5,765
| New | +$749K | 0.32% | 68 |
|
|
2022
Q4 | $758K | Hold |
5,775
| – | – | 0.38% | 66 |
|
|
2022
Q3 | $675K | Hold |
5,775
| – | – | 0.38% | 71 |
|
|
2022
Q2 | $679K | Hold |
5,775
| – | – | 0.33% | 79 |
|
|
2022
Q1 | $752K | Hold |
5,775
| – | – | 0.29% | 78 |
|
|
2021
Q4 | $881K | Hold |
5,775
| – | – | 0.3% | 76 |
|
|
2021
Q3 | $934K | Hold |
5,775
| – | – | 0.35% | 73 |
|
|
2021
Q2 | $945K | Hold |
5,775
| – | – | 0.34% | 72 |
|
|
2021
Q1 | $869K | Hold |
5,775
| – | – | 0.34% | 73 |
|
|
2020
Q4 | $875K | Hold |
5,775
| – | – | 0.36% | 71 |
|
|
2020
Q3 | $782K | Hold |
5,775
| – | – | 0.36% | 70 |
|
|
2020
Q2 | $789K | Sell |
5,775
-665
| -10% | -$84.8K | 0.39% | 68 |
|
|
2020
Q1 | $694K | Hold |
6,440
| – | – | 0.46% | 61 |
|
|
2019
Q4 | $776K | Sell |
6,440
-75
| -1% | -$8.37K | 0.36% | 70 |
|
|
2019
Q3 | $648K | Sell |
6,515
-3,700
| -36% | -$387K | 0.33% | 76 |
|
|
2019
Q2 | $1.11M | Sell |
10,215
-100
| -1% | -$10.6K | 0.59% | 51 |
|
|
2019
Q1 | $1.15M | Sell |
10,315
-570
| -5% | -$62.5K | 0.59% | 55 |
|
|
2018
Q4 | $1.05M | Sell |
10,885
-635
| -6% | -$67.4K | 0.66% | 51 |
|
|
2018
Q3 | $1.41M | Sell |
11,520
-600
| -5% | -$70.7K | 0.66% | 49 |
|
|
2018
Q2 | $1.33M | Sell |
12,120
-1,200
| -9% | -$128K | 0.63% | 50 |
|
|
2018
Q1 | $1.42M | Sell |
13,320
-285
| -2% | -$31.6K | 0.66% | 46 |
|
|
2017
Q4 | $1.45M | Sell |
13,605
-450
| -3% | -$48.1K | 0.66% | 47 |
|
|
2017
Q3 | $1.56M | Buy |
14,055
+3,180
| +29% | +$340K | 0.74% | 45 |
|
|
2017
Q2 | $1.12M | Buy |
10,875
+1,500
| +16% | +$148K | 0.54% | 52 |
|
|
2017
Q1 | $916K | Buy |
9,375
+1,065
| +13% | +$102K | 0.49% | 56 |
|
|
2016
Q4 | $735K | Buy |
8,310
+1,410
| +20% | +$128K | 0.4% | 63 |
|
|
2016
Q3 | $666K | Buy |
6,900
+900
| +15% | +$85.6K | 0.38% | 66 |
|
|
2016
Q2 | $515K | Buy |
6,000
+780
| +15% | +$70K | 0.3% | 78 |
|
|
2016
Q1 | $454K | Buy |
5,220
+900
| +21% | +$80.5K | 0.27% | 85 |
|
|
2015
Q4 | $487K | Buy |
4,320
+1,185
| +38% | +$129K | 0.28% | 86 |
|
|
2015
Q3 | $317K | Buy |
3,135
+1,170
| +60% | +$140K | 0.21% | 99 |
|
|
2015
Q2 | $242K | Buy |
+1,965
| New | +$235K | 0.13% | 135 |
|
Other funds holding IBB
CB
Mathes Company's IBB Position: Q2 2024 in Review
Mathes Company sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 5,765 shares — an estimated $791K sold.
Mathes Company first reported a position in IBB in Q2 2015 and held it in 35 quarters. The position peaked at $1.56M in Q3 2017. 894 funds tracked by Wall St. Rank hold IBB as of Q2 2024.
- Mathes Company reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
- Mathes Company sold 5,765 iShares Biotechnology ETF shares in Q2 2024, an estimated $791K.
- Mathes Company first reported a position in iShares Biotechnology ETF in Q2 2015 and held it in 35 quarters.
- Mathes Company's iShares Biotechnology ETF position peaked at $1.56M in Q3 2017.
- 894 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.
Based on Mathes Company's 13F filing for Q2 2024, filed 12 Aug 2024.